There is currently no evidence regarding the extent to which bone metastases affect the incidence of side effects during pemetrexed therapy, and patients with lung adenocarcinoma might benefit from a treatment regimen without pemetrexed or from closer monitoring during therapy, in line with a personalized treatment app...
C. Riedel, Christian Neumann, R. Heller et al.· Cancers· 0 citations
Lonca demonstrated a favorable safety profile with moderate efficacy in heavily pretreated patients, while enabling timely access to subsequent therapy, efficacy in earlier lines with combination partners may further increase response rates and durability of response.
E. Shumilov, Lina J. Kolloch, Philipp Faustmann et al.· Blood Advances· 0 citations
This review connects expert perspectives with targeted literature to outline how these emerging methods advance precision oncology and identifies the technical, struc-tural, and clinical requirements for their implementation in clinical use, and highlights how they can improve the quality, speed and accessibility of MT...
J. Vorwerk, L. Leypoldt, Johanna Schwandt et al.· Oncology Research and Treatm...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.